Clinical trial
Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the…
NCT00157976 · Miravant Pharmaceuticals, Industry · Unknown status
Key facts
| NCT number | NCT00157976 |
|---|---|
| Title | Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration |
| Official title | A Phase III Randomized, Multicenter, Multinational, Double-Masked, Placebo-Controlled Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Classic and Occult Subfoveal Choroidal Neovascularization Associated With AMD |
| Lead sponsor | Miravant Pharmaceuticals, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Macular Degeneration |
| Intervention type | Drug |
| Interventions | Photrex (rostaporfin) |
| Enrollment | 660 |
| Start date | Sep 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Dec 1, 2005 |
| Countries | Bulgaria, Czechia, Poland, Romania |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: